Positions 76–95 of 95.
SURPASS — 22 things I got wrong before I got it right. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix tables and…
Trying to get a straight answer on this: help me understand SURMOUNT, I have read the wiki twice. Relative risk reduction without the baseline rate is uninterpretable.…
Thinking out loud about this: SURPASS — 12 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing…
SELECT: what the trials say vs what this community says — a position I have arrived at slowly and would like tested. Why comparing across trials almost never works,…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsSURPASS — 9 things I got wrong before I got it right. Change my mind, genuinely — I have no stake in being right about this. Started keeping the trial identifiers…
Trying to get a straight answer on this: genuine question about TRIUMPH that I am slightly embarrassed to ask. Why comparing across trials almost never works, with the…
Thinking out loud about this: the endpoint advice in here is 3 years out of date. 3 years — those are the numbers, and they are the ones I am willing to defend.…
write the concentration on the vial. that is the whole post. Two minutes of reading now saves an argument later. Quoted a figure here confidently, got asked whether it…
the STEP thing finally clicked for me and I want to write it down. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix…
The title is the argument: reading SURMOUNT threads from 2024 and half of it aged badly. Here is the rest of it. Discontinuation rates are a tolerability result. A…
unpopular opinion: most of what gets said here about hazard ratio is guesswork, which sounds obvious until you try to state the evidence for it. Went looking for the…
how much of what we believe about endpoint actually comes from SURMOUNT threads. I am not trying to be the "source?" guy. I would just like a source. How to read one of…
The title is the whole question — genuine question about TRIUMPH that I am slightly embarrassed to ask — but here is why I am asking. Discontinuation rates are a…
proposal — a flair for FLOW posts, and it will stay as it is unless somebody makes the case to change it. Open-label extensions lose their randomisation. Anybody still…
Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Relative risk reduction without the baseline rate is…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netthe FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open. The discontinuation numbers…
Posting this as a discussion rather than a claim: three years of SURMOUNT threads, summarised so you do not have to read them. Relative risk reduction without the…
The title is the whole question — help me understand SURMOUNT, I have read the wiki twice — but here is why I am asking. Discontinuation rates are a tolerability…
Thinking out loud about this: SURPASS — 10 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing…
FLOW (Perkovic et al., N Engl J Med , 2024) reported a hazard ratio of 0.76 for the composite kidney endpoint in people with type 2 diabetes and chronic kidney disease.…
Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference